Zhixing Liang
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Low-dose bevacizumab plus atezolizumab enhances transarterial chemoembolization in HCC via correcting vascular-immune niche dysfunction.
Journal: Journal of hepatology
Published: February 09, 2026
Radiation-induced CD200+ tumor-associated macrophages suppress eosinophil-mediated antitumor immunity through CD200R signaling in hepatocellular carcinoma.
Journal: Cellular & molecular immunology
Published: October 29, 2025
FXR-mediated antigen-specific CD8+ T cell enhances antitumor immunity in intrahepatic cholangiocarcinoma.
Journal: Journal for immunotherapy of cancer
Published: October 23, 2025
Immune checkpoint inhibitors in hepatocellular carcinoma therapy: resistance mechanisms, liver transplantation challenges and management strategies.
Journal: Cancer drug resistance (Alhambra, Calif.)
Published: July 18, 2025
Multi-faceted nanodrug reinforcing metalloimmunotherapy for hepatocellular carcinoma.
Journal: Biomaterials
Published: June 01, 2025
N6-methyladenosine-mediated up-regulation of ARRB2 regulates intrahepatic cholangiocarcinoma malignant progression and pemigatinib resistance through MAPK and Hippo signaling pathways.
Journal: Cell death & disease
Published: April 30, 2025
Tissue-resident peripheral helper T cells foster hepatocellular carcinoma immune evasion by promoting regulatory B-cell expansion.
Journal: Chinese medical journal
Published: December 26, 2024
CRSP8-driven fatty acid metabolism reprogramming enhances hepatocellular carcinoma progression by inhibiting RAN-mediated PPARα nucleus-cytoplasm shuttling.
Journal: Journal of experimental & clinical cancer research : CR
Published: November 07, 2024
Association between changes in body composition and progression of liver fibrosis in patients with type 2 diabetes mellitus.
Journal: Frontiers in nutrition
Published: August 05, 2024
Dynamic network biomarker C1QTNF1 regulates tumor formation at the tipping point of hepatocellular carcinoma.
Journal: Biomolecules & biomedicine
Published: November 28, 2023
Prediction model for hepatocellular carcinoma recurrence after hepatectomy: Machine learning-based development and interpretation study.
Journal: Heliyon
Published: May 24, 2023
Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8+ exhausted-like T cells.
Journal: Nature communications
Published: March 31, 2023
Last Updated: 09/26/2026